LEXINGTON, Mass., March 7, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and full year 2017 financial results before the market opens on Thursday, March 15, 2018.

- Combination trial accrual completed in first cohort of patients - Commercial grade AGEN1884 and AGEN2034 to be available by mid-year - Non-exclusive access to partners for clinical and commercial supplies LEXINGTON, Mass., Jan. 22, 2018 / PRNewswire / -- Agenus Inc.

LEXINGTON, Mass., Jan. 22, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).

LEXINGTON, Mass., Jan. 8, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).

LEXINGTON, Mass., Jan. 4, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle, Head of Translational Medicine and Bioinformatics ,  will participate in a panel

-- Hagop Youssoufian, MD, named Senior Clinical Strategist -- John Castle, Ph.D., appointed as Head of Translational Medicine and Bioinformatics -- Tyler Curiel, MD, MPH named Senior Strategist for Translational and Biomarker Development LEXINGTON, Mass., Jan. 3, 2018 / PRNewswire / -- Agenus Inc.

LEXINGTON, Mass., Nov. 15, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license

- Plans to file first BLA 2H2019 - Combination trials in 1L NSCLC, monotherapy trials in 2L cervical cancer and cutaneous squamous cell carcinoma advancing - Data presented at SITC on pharmacologic activity of AGEN CTLA-4 and PD-1 antibodies - GMP clinical grade supply available for Agenus and

LEXINGTON, Mass., Nov. 8, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus, and Michael Plater,

Agenus to host conference call and webcast today at 11am ET LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results

LEXINGTON, Mass., Oct. 26, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2017 financial results before the market opens on Tuesday, November 7, 2017.

LEXINGTON, Mass., Oct. 25, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices

Bruno Lucidi, previously of Idenix, Pharmasset and BMS named AgenTus CEO LEXINGTON, Mass., Oct. 23, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN) Chairman and Chief Executive Officer (CEO) Garo Armen Ph.D. announces the appointment of Bruno Lucidi as CEO of AgenTus Therapeutics, Inc., a

Bruno Lucidi, previously of Idenix, Pharmasset and BMS named AgenTus CEO LEXINGTON, Mass., Oct. 23, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of a subsidiary

- SHINGRIX containing QS-21 Stimulon® demonstrates remarkable efficacy of greater than 90% in pooled studies against shingles - Shingles is a major public health issue in the US, impacting as many as 1 in 3 adults over the age of 50 years LEXINGTON, Mass., Oct.

First approval for a vaccine enhanced with QS-21 Stimulon® LEXINGTON, Mass., Oct. 13, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Health Canada granted marketing authorization

LEXINGTON, Mass., Sept. 19, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's Leadership will present and host one-on-one meetings at two healthcare

LEXINGTON, Mass., Sept. 13, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that GlaxoSmithKline's (GSK) shingles vaccine candidate, Shingrix, containing Agenus' proprietary immune

Earnings Conference call at 11am ET today LEXINGTON, Mass. , Aug. 3, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for the second

LEXINGTON, Mass., July 27, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2017 financial results before the market opens on Thursday, August 3, 2017.

-GSK to present the revaccination study results at the CDC's Advisory Meeting on patients who had previously received standard of care treatment- LEXINGTON, Mass., June 21, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies

LEXINGTON, Mass., June 21, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m.

LEXINGTON, Mass., June 5, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the results from an ongoing Phase 1 dose-escalation trial for its anti-CTLA-4 antibody, AGEN1884, in patients

LEXINGTON, Mass., June 1, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the Company will present at the following conferences to be held in New York City, USA: The 2017

LEXINGTON, Mass., May 22, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that an abstract on its anti-CTLA-4 antibody, AGEN1884 was accepted for poster presentation.